Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Jara-Lazaro AR, Thilagaratnam S, Tan PH. Breast cancer in Singapore: some perspectives. Breast Cancer. 2010;17(1):23–28. doi: 10.1007/s12282-009-0155-3
   PubMed Web of Science ®Google Scholar
• Shih V, Chan A, Xie F, et al. Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore. Value Health Reg Issues. 2012;1(1):46–53. doi: 10.1016/j.vhri.2012.03.013
   PubMedGoogle Scholar
• National Registry of Diseases Office. Singapore cancer Registry annual report 2019. Singapore: National Registry of Diseases Office.
   Google Scholar
• Chow WL, Tan S-M, Aung KCY, et al. Factors influencing quality of life of Asian breast cancer patients and their caregivers at diagnosis: perceived medical and psychosocial needs. Singapore Med J. 2020;61(10):532. doi: 10.11622/smedj.2019099
   PubMed Web of Science ®Google Scholar
• Vondeling GT, Menezes GL, Dvortsin EP, et al. Burden of early, advanced and metastatic breast cancer in the Netherlands. BMC Cancer. 2018;18(1):262. doi: 10.1186/s12885-018-4158-3
   PubMed Web of Science ®Google Scholar
• Blumen H, Fitch K, Polkus V. Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am Health Drug Benefits. 2016;9(1):23–32.
   PubMed Web of Science ®Google Scholar
• Rakha EA, Pinder SE, Bartlett JM, et al. Updated UK recommendations for HER2 assessment in breast cancer. J Clin Pathol. 2015;68(2):93–99. doi: 10.1136/jclinpath-2014-202571
   PubMed Web of Science ®Google Scholar
• Slamon D, Clark G, Wong S, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182. doi: 10.1126/science.3798106
   PubMed Web of Science ®Google Scholar
• Martínez-Sáez O, Prat A. Current and future management of HER2-positive metastatic breast cancer. J Oncol Pract. 2021;17(10):594–604. doi: 10.1200/OP.21.00172
   Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–1220. doi: 10.1093/annonc/mdz173
   PubMed Web of Science ®Google Scholar
• Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39(13):1485–1505. doi: 10.1200/JCO.20.03399
   PubMed Web of Science ®Google Scholar
• National Comphrehensive Cancer Network (NCCN). Clinical practice guidelines in Oncology (breast cancer). United States: NCCN; 2022.
   Google Scholar
• Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69(24):9330–9336. doi: 10.1158/0008-5472.CAN-08-4597
   PubMed Web of Science ®Google Scholar
• Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236–244. doi: 10.1016/S1470-2045(11)70033-X
   PubMed Web of Science ®Google Scholar
• Takada M, Ishiguro H, Nagai S, et al. Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study). Breast Cancer Res Treat. 2014;145(1):143–53. doi: 10.1007/s10549-014-2907-9
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–2284. doi: 10.1093/annonc/mdt182
   PubMed Web of Science ®Google Scholar
• Swain SM, Ewer MS, Viale G, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018;29(3):646–653. doi: 10.1093/annonc/mdx773
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32. doi: 10.1016/S1470-2045(11)70336-9
   PubMed Web of Science ®Google Scholar
• Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial. JAMA Oncol. 2020;6(3):e193692. doi: 10.1001/jamaoncol.2019.3692
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800. doi: 10.1016/S1470-2045(16)00163-7
   PubMed Web of Science ®Google Scholar
• Health Sciences Authority (HSA) Singapore. Pertuzumab registration (SIN14501P). Singapore: HSA; 2014.
   Google Scholar
• Singapore Ministry of Health Cancer Drug List [Internet]. Singapore: Singapore Ministry of Health; [cited 2023 Apr 28]. Available from: https://www.moh.gov.sg/home/our-healthcare-system/medishield-life/what-is-medishield-life/what-medishield-life-benefits/cancer-drug-list
   Google Scholar
• Pearce F, Lin L, Teo E, et al. Health technology assessment and its use in drug policies: Singapore. Value Health Reg Issues. 2019;18:176–183. doi: 10.1016/j.vhri.2018.03.007
   PubMedGoogle Scholar
• Attard C, Pepper A, Brown S, et al. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. J Med Econ. 2015;18(3):173–188. doi: 10.3111/13696998.2014.979938
   PubMed Web of Science ®Google Scholar
• Sussell JA, Roth JA, Meyer CS, et al. Assessment of the cost-effectiveness of HER2-targeted treatment pathways in the neoadjuvant treatment of high-risk HER2-positive early-stage breast cancer. Adv Ther. 2022;39(3):1375–1392. doi: 10.1007/s12325-022-02047-y
   PubMed Web of Science ®Google Scholar
• Han H-S, Lee K-W, Kim JH, et al. Weight changes after adjuvant treatment in Korean women with early breast cancer. Breast Cancer Res Treat. 2009;114(1):147–153. doi: 10.1007/s10549-008-9984-6
   PubMed Web of Science ®Google Scholar
• Sun LM, Chen HJ, Liang JA, et al. Association of tamoxifen use and increased diabetes among Asian women diagnosed with breast cancer. Br J Cancer. 2014;111(9):1836–1842. doi: 10.1038/bjc.2014.488
   PubMed Web of Science ®Google Scholar
• Yeo W, Lei YY, Cheng AC, et al. Changes in body weight over 18-months follow-up among Chinese patients after breast cancer diagnosis. Ann Oncol. 2018;29:viii81–viii82. doi: 10.1093/annonc/mdy270.251
   Web of Science ®Google Scholar
• Youlden DR, Cramb SM, Yip CH, et al. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 2014;11(2):101–115. doi: 10.7497/j.issn.2095-3941.2014.02.005
   PubMedGoogle Scholar
• Singapore Department of Statistics (Singstat). Complete life Tables for Singapore resident population. Singapore: Singstat; 2020-2021.
   Google Scholar
• Cheng LJ, Loke L, Lim EH, et al. Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):449–456. doi: 10.1080/14737167.2021.1880323
   PubMed Web of Science ®Google Scholar
• Agency for Care Effectiveness (ACE). Procedures and guidelines for company submissions to the Agency for Care effectiveness for funding consideration. Singapore: ACE; 2022.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424). UK: NICE; 2016.
   Google Scholar
• Health Sciences Authority (HSA) Singapore. Trastuzumab registration (SIN11028P). Singapore: HSA; 2021.
   Google Scholar
• Swain SM, Macharia H, Cortes J, et al., editors. P1-18-01: risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: a retrospective exploratory analysis. Poster presented at: San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX.
   Google Scholar
• von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617–628. doi: 10.1056/NEJMoa1814017
   PubMed Web of Science ®Google Scholar
• Piccart M, Procter M, Fumagalli D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years’ follow-up. J Clin Oncol. 2021;39(13):1448–1457. doi: 10.1200/JCO.20.01204
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458). UK: NICE; 2017.
   Google Scholar
• Hamilton SN, Tyldesley S, Li D, et al. Second malignancies after adjuvant radiation therapy for early stage breast cancer: is there increased risk with addition of regional radiation to local radiation? Int J Radiat Oncol. 2015;91(5):977–985. doi: 10.1016/j.ijrobp.2014.12.051
   PubMed Web of Science ®Google Scholar
• Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732–742. doi: 10.1016/S1470-2045(17)30312-1
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2015;372(8):724–734. doi: 10.1056/NEJMoa1413513
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265–4274. doi: 10.1200/JCO.2005.04.173
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683–690. doi: 10.1038/sj.bjc.6603326
   PubMed Web of Science ®Google Scholar
• Abdin E, Subramaniam M, Vaingankar JA, et al. Population norms for the EQ-5D index scores using Singapore preference weights. Qual Life Res. 2015;24(6):1545–1553. doi: 10.1007/s11136-014-0859-5
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al., editors. S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Abstract presented at: San Antonio Breast Cancer Symposium; 2015 Dec 8-12; San Antonio, TX.
   Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–1205. doi: 10.1016/S0140-6736(16)32616-2
   PubMed Web of Science ®Google Scholar
• Garrison LP Jr, Babigumira J, Tournier C, et al. Cost-effectiveness analysis of pertuzumab with trastuzumab and chemotherapy compared to trastuzumab and chemotherapy in the adjuvant treatment of HER2-positive breast cancer in the United States. Value Health. 2019;22(4):408–415. doi: 10.1016/j.jval.2018.11.014
   PubMed Web of Science ®Google Scholar
• Agency for Care Effectiveness (ACE). Process Methods and resource sheet. Singapore: ACE; 2022.
   Google Scholar
• Tan DS, Chan JJ, Hettle R, et al. Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore. J Gynecol Oncol. 2021;32(2):e27. doi: 10.3802/jgo.2021.32.e27
   PubMed Web of Science ®Google Scholar
• Viswambaram A, Wee YR, Lim S. PMU20 is there an implicit willingness-to-pay threshold in Singapore? Value Health Reg Issues. 2020;22:S72. doi: 10.1016/j.vhri.2020.07.378
   Google Scholar
• Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. Am J Clin Oncol. 2021;39(13):1485–1505. doi: 10.1200/JCO.20.03399
   PubMed Web of Science ®Google Scholar
• Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68(14):5878–5887. doi: 10.1158/0008-5472.CAN-08-0380
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172. doi: 10.1016/S0140-6736(13)62422-8
   PubMed Web of Science ®Google Scholar
• Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26(12):2838–2848. doi: 10.1158/1078-0432.CCR-19-3492
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569). UK: NICE; 2019.
   Google Scholar
• Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422–437. doi: 10.1002/hec.1481
   PubMed Web of Science ®Google Scholar
• Pan-Canadian Oncology Drug Review (PCODR). Final economic guidance report: pertuzumab (Perjeta) neoadjuvant breast cancer. Canada: Canadian Agency for Drugs and Technologies in Health (CADTH); 2015.
   Google Scholar
• Pan-Canadian Oncology Drug Review (PCODR). Final Economic Guidance Report: Pertuzumab–Trastuzumab for Early Breast Cancer. Canada: Canadian Agency for Drugs and Technologies in Health (CADTH); 2018.
   Google Scholar
• Xin WR, Kwok LL, Yong WF. Screening uptake differences are not implicated in poorer breast cancer outcomes among Singaporean Malay women. J Breast Cancer. 2017;20(2):183–191. doi: 10.4048/jbc.2017.20.2.183
   PubMed Web of Science ®Google Scholar